OTCQB:CBDS - OTCQB:DCTH - OTCQB:MRRCF - OTCQB:PRVCF - OTCQX:JBSAY - OTCQX:RHHBY - OTCQX:SLSDF - PINK:NUGL - 24/7 Market News

Venture Breakfast Bits, by 24/7 Market News

2018-10-15T10:04:42+00:00 Oct. 15, 2018 10:02AM EST|

Venture Market News for October 15, 2018

  • Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases. These centers join Stanford Medical Center in initiating enrollment in the amended trial, giving the company wide geographic coverage in the United States. Joining Stanford Medical Center are:

Full press release

  • Marijuana Lozenge Patented by Cannabis Sativa

MESQUITE, NV / ACCESSWIRE / October 15, 2018 / Cannabis Sativa, Inc. (OTCQB: CBDS) is pleased to announce that the United States Patent Office will issue to CBDS the US Patent number 10105343 titled "Cannabis based compositions and methods of treating hypertension" on October 23, 2018.

Full press release

  • Wayland Signs Minimum 9,000 kilograms Supply Agreement with Cannamedical for Export of Product from Canada to Germany

TORONTO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company) is pleased to announce that it has entered into an agreement to supply Cannamedical Pharma GmbH, a licensed, privately owned importer and distributor of cannabis in Germany to over 2,200 pharmacies with a minimum of 9,000 kilograms of EU-GMP certified cannabis flowers over a three year term. The companies have completed mandatory quality assurance and control audits and have scheduled the first shipment in December of 2018.

Full press release

  • JBS USA ANNOUNCES THE RENEWAL OF ITS US$900 MILLION REVOLVING CREDIT FACILITY IN THE UNITED STATES AND A NEW REVOLVING CREDIT FACILITY OF AUD$200 MILLION IN AUSTRALIA

October 15, 2018- OTC Disclosure & News Service- Sao Paulo, Brazil —

This release includes additional documents. Select the link(s) below to view.

Material Fact - JBS USA Credit Facilities.pdf

  • PreveCeutical to Visit Penta 5 Group’s Packaging Facility for Due Diligence on Proposed Acquisition

October 15, 2018- OTC Disclosure & News Service- Vancouver, BC, Canada —

This release includes additional documents. Select the link(s) below to view.

PreveCeutical to Visit Penta 5 Group’s Packaging Facility .pdf  

  • Select Sands Announces Temporary Furlough at Sandtown

VANCOUVER, B.C., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Select Sands Corp. ("Select Sands" or the "Company") (TSXV: SNS | OTCQX: SLSDF) announced today that it has placed 26 employees at its Arkansas operations on temporary furlough until further notice.  This necessary step results from the current industry-wide market disruption, which has impacted demand for Select Sands' Northern White frac sand.  Shipments and limited production continue, while the Company continues to pursue additional opportunities.

Full press release

  • NUGL Enters into Letter of Intent to Acquire National Cannabis Publication Company

LOS ANGELES, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NUGL Inc. (OTC: NUGL) (the “Company”), the cannabis industry's new standard of technology, today reports it has entered into a binding letter of intent (“LOI”) to purchase Nichols Publishing Company , Inc. (“Nichols Publishing”), an Iowa based corporation that publishes industry known magazine publications such as the Professional Marijuana Grower and Garden & Greenhouse.

Full press release

  • SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology

- Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise

- SQZ to receive up to $125 million in upfront and near-term milestone payments

WATERTOWN, Mass., Oct. 15, 2018 /PRNewswire/ -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced the expansion of its collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) in cellular therapy. The expanded partnership furthers the synergistic combination of SQZ's innovation and expertise in cell therapy with Roche's cancer immunotherapy expertise. Under the terms, SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications.

Full press release

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice.   24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan," or "planned," "will," or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements

CONTACT:

24/7 Market News

Editor@247marketnews.com

Send this to a friend

Hi, this may be interesting you: Kraig Biocraft Laboratories’ New R&D Facility Extends Its Competitive Advantages and Prepares for Large Scale Production! This is the link: https://www.247marketnews.com/kraig-biocraft-laboratories-new-rd-facility-extends-its-competitive-advantages-and-prepares-for-large-scale-production/